Skip to main content
Top
Published in: Familial Cancer 2/2024

25-04-2024 | Ovarian Cancer | Review

Psychosocial barriers and facilitators for cascade genetic testing in hereditary breast and ovarian cancer: a scoping review

Authors: Agani Afaya, Sung-Won Kim, Hyung Seok Park, Myong Cheol Lim, Mi Sook Jung, Eun Ji Nam, Ji Soo Park, Joon Jeong, Jai Min Ryu, JiSun Kim, Jihye Kim, Minkyoung Kim, Juhye Jin, Jeehee Han, Soo Yeon Kim, Sun-Young Park, Maria C. Katapodi, Sue Kim, the K-CASCADE consortium

Published in: Familial Cancer | Issue 2/2024

Login to get access

Abstract

Despite increased awareness and availability of genetic testing for hereditary breast and ovarian cancer (HBOC) syndrome for over 20 years, there is still significant underuse of cascade genetic testing among at-risk relatives. This scoping review synthesized evidence regarding psychosocial barriers and facilitators of family communication and/or uptake of cascade genetic testing in relatives from HBOC families. Search terms included ‘hereditary breast and ovarian cancer’ and ‘cascade genetic testing’ for studies published from 2012–2022. Through searching common databases, and manual search of references, 480 studies were identified after excluding duplications. Each article was reviewed by two researchers independently and 20 studies were included in the final analysis. CASP, RoBANS 2.0, RoB 2.0, and MMAT were used to assess the quality of included studies. A convergent data synthesis method was used to integrate evidence from quantitative and narrative data into categories and subcategories. Evidence points to 3 categories and 12 subcategories of psychosocial barriers and facilitators for cascade testing: (1) facilitators (belief in health protection and prevention; family closeness; decisional empowerment; family support, sense of responsibility; self-efficacy; supportive health professionals); (2) bidirectional concepts (information; perception of genetic/cancer consequences; negative emotions and attitude); and (3) barriers (negative reactions from family and negative family dynamics). Healthcare providers need to systematically evaluate these psychosocial factors, strengthen facilitators and alleviate barriers to promote informed decision-making for communication of genetic test results and uptake of genetic testing. Bidirectional factors merit special consideration and tailored approaches, as they can potentially have a positive or negative influence on family communication and uptake of genetic testing.
Appendix
Available only for authorised users
Literature
1.
go back to reference Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis D (2019) SEER cancer statistics review, 1975–2016, National Cancer Institute. Bethesda, MD 2020:1–10 Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis D (2019) SEER cancer statistics review, 1975–2016, National Cancer Institute. Bethesda, MD 2020:1–10
2.
go back to reference Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416PubMedCrossRef Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416PubMedCrossRef
3.
go back to reference Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130PubMedPubMedCentralCrossRef Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130PubMedPubMedCentralCrossRef
4.
go back to reference Childers CP, Childers KK, Maggard-Gibbons M, Macinko J (2017) National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol 35(34):3800–3806PubMedPubMedCentralCrossRef Childers CP, Childers KK, Maggard-Gibbons M, Macinko J (2017) National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol 35(34):3800–3806PubMedPubMedCentralCrossRef
5.
go back to reference Obstetricians ACo, Gynecologists, Practice CoG (2018) Cascade testing: testing women for known hereditary genetic mutations associated with cancer. ACOG committee opinion no. 727. Obstet Gynecol Surv 73(4):211–212CrossRef Obstetricians ACo, Gynecologists, Practice CoG (2018) Cascade testing: testing women for known hereditary genetic mutations associated with cancer. ACOG committee opinion no. 727. Obstet Gynecol Surv 73(4):211–212CrossRef
6.
go back to reference Caswell-Jin JL, Zimmer AD, Stedden W, Kingham KE, Zhou AY, Kurian AW (2019) Cascade genetic testing of relatives for hereditary cancer risk: results of an online initiative. J Natl Cancer Inst 111(1):95–98PubMedCrossRef Caswell-Jin JL, Zimmer AD, Stedden W, Kingham KE, Zhou AY, Kurian AW (2019) Cascade genetic testing of relatives for hereditary cancer risk: results of an online initiative. J Natl Cancer Inst 111(1):95–98PubMedCrossRef
7.
go back to reference Srinivasan S, Won NY, Dotson WD, Wright ST, Roberts MC (2020) Barriers and facilitators for cascade testing in genetic conditions: a systematic review. Eur J Hum Genet 28(12):1631–1644PubMedPubMedCentralCrossRef Srinivasan S, Won NY, Dotson WD, Wright ST, Roberts MC (2020) Barriers and facilitators for cascade testing in genetic conditions: a systematic review. Eur J Hum Genet 28(12):1631–1644PubMedPubMedCentralCrossRef
8.
go back to reference Makhnoon S, Tran G, Levin B, Mattie KD, Dreyer B, Volk RJ, Grana G, Arun BK, Peterson SK (2021) Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes. Cancer 127(19):3605–3613PubMedCrossRef Makhnoon S, Tran G, Levin B, Mattie KD, Dreyer B, Volk RJ, Grana G, Arun BK, Peterson SK (2021) Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes. Cancer 127(19):3605–3613PubMedCrossRef
9.
go back to reference Trottier M, Lunn J, Butler R, Curling D, Turnquest T, Royer R, Akbari MR, Donenberg T, Hurley J, Narod SA (2015) Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas. Clin Genet 88(2):182–186PubMedCrossRef Trottier M, Lunn J, Butler R, Curling D, Turnquest T, Royer R, Akbari MR, Donenberg T, Hurley J, Narod SA (2015) Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas. Clin Genet 88(2):182–186PubMedCrossRef
10.
go back to reference Baroutsou V, Underhill-Blazey ML, Appenzeller-Herzog C, Katapodi MC (2021) Interventions facilitating family communication of genetic testing results and cascade screening in hereditary breast/ovarian cancer or lynch syndrome: a systematic review and meta-analysis. Cancers (Basel) 13(4):925PubMedCrossRef Baroutsou V, Underhill-Blazey ML, Appenzeller-Herzog C, Katapodi MC (2021) Interventions facilitating family communication of genetic testing results and cascade screening in hereditary breast/ovarian cancer or lynch syndrome: a systematic review and meta-analysis. Cancers (Basel) 13(4):925PubMedCrossRef
11.
go back to reference Katz SJ, Kurian AW, Morrow M (2015) Treatment decision making and genetic testing for breast cancer: mainstreaming mutations. JAMA 314(10):997–998PubMedCrossRef Katz SJ, Kurian AW, Morrow M (2015) Treatment decision making and genetic testing for breast cancer: mainstreaming mutations. JAMA 314(10):997–998PubMedCrossRef
12.
go back to reference van den Marleen Heuvel L, Stemkens D, van Zelst-Stams WAG, Willeboordse F, Christiaans I (2020) How to inform at-risk relatives? attitudes of 1379 dutch patients, relatives, and members of the general population. J Genet Couns 29(5):786–799CrossRef van den Marleen Heuvel L, Stemkens D, van Zelst-Stams WAG, Willeboordse F, Christiaans I (2020) How to inform at-risk relatives? attitudes of 1379 dutch patients, relatives, and members of the general population. J Genet Couns 29(5):786–799CrossRef
13.
go back to reference Sanz J, Ramón y Cajal T, Torres A, Darder E, Gadea N, Velasco A, Fortuny D, López C, Fisas D, Brunet J et al (2010) Uptake of predictive testing among relatives of BRCA1 and BRCA2 families: a multicenter study in northeastern spain. Fam Cancer 9(3):297–304PubMedCrossRef Sanz J, Ramón y Cajal T, Torres A, Darder E, Gadea N, Velasco A, Fortuny D, López C, Fisas D, Brunet J et al (2010) Uptake of predictive testing among relatives of BRCA1 and BRCA2 families: a multicenter study in northeastern spain. Fam Cancer 9(3):297–304PubMedCrossRef
14.
go back to reference Sermijn E, Delesie L, Deschepper E, Pauwels I, Bonduelle M, Teugels E, De Grève J (2016) The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety. Fam Cancer 15(2):155–162PubMedPubMedCentralCrossRef Sermijn E, Delesie L, Deschepper E, Pauwels I, Bonduelle M, Teugels E, De Grève J (2016) The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety. Fam Cancer 15(2):155–162PubMedPubMedCentralCrossRef
15.
go back to reference Menko FH, Aalfs CM, Henneman L, Stol Y, Wijdenes M, Otten E, Ploegmakers MM, Legemaate J, Smets EM, de Wert GM et al (2013) Informing family members of individuals with lynch syndrome: a guideline for clinical geneticists. Fam Cancer 12(2):319–324PubMedCrossRef Menko FH, Aalfs CM, Henneman L, Stol Y, Wijdenes M, Otten E, Ploegmakers MM, Legemaate J, Smets EM, de Wert GM et al (2013) Informing family members of individuals with lynch syndrome: a guideline for clinical geneticists. Fam Cancer 12(2):319–324PubMedCrossRef
16.
go back to reference Peters M, Godfrey C, McInerney P, Soares C, Khalil H, Parker D (2015) The joanna briggs institute reviewers’ manual 2015: methodology for jbi scoping reviews. The Joanna Briggs Institute, Adelaide, SA Australia Peters M, Godfrey C, McInerney P, Soares C, Khalil H, Parker D (2015) The joanna briggs institute reviewers’ manual 2015: methodology for jbi scoping reviews. The Joanna Briggs Institute, Adelaide, SA Australia
17.
go back to reference Arksey H, O’Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol 8(1):19–32CrossRef Arksey H, O’Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol 8(1):19–32CrossRef
18.
go back to reference Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169(7):467–473PubMedCrossRef Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169(7):467–473PubMedCrossRef
20.
go back to reference Hong QN, Pluye P, Bujold M, Wassef M (2017) Convergent and sequential synthesis designs: implications for conducting and reporting systematic reviews of qualitative and quantitative evidence. Syst Rev 6(1):61PubMedPubMedCentralCrossRef Hong QN, Pluye P, Bujold M, Wassef M (2017) Convergent and sequential synthesis designs: implications for conducting and reporting systematic reviews of qualitative and quantitative evidence. Syst Rev 6(1):61PubMedPubMedCentralCrossRef
22.
go back to reference Service HIRA (2013) Revision of study design algorithm tool and bias risk assessment tool. Health Insurance Review & Assessment Service, Seoul Service HIRA (2013) Revision of study design algorithm tool and bias risk assessment tool. Health Insurance Review & Assessment Service, Seoul
23.
go back to reference Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, Jang BH, Son HJ (2013) Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 66(4):408–414PubMedCrossRef Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, Jang BH, Son HJ (2013) Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 66(4):408–414PubMedCrossRef
24.
go back to reference Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898CrossRefPubMed Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898CrossRefPubMed
25.
go back to reference Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, Gagnon M-P, Griffiths F, Nicolau B, O’Cathain A (2018) The mixed methods appraisal tool (MMAT) version 2018 for information professionals and researchers. Educ Inf 34(4):285–291 Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, Gagnon M-P, Griffiths F, Nicolau B, O’Cathain A (2018) The mixed methods appraisal tool (MMAT) version 2018 for information professionals and researchers. Educ Inf 34(4):285–291
26.
go back to reference Alegre N, Perre PV, Bignon YJ, Michel A, Galibert V, Mophawe O, Corsini C, Coupier I, Chiesa J, Robert L et al (2019) Psychosocial and clinical factors of probands impacting intrafamilial disclosure and uptake of genetic testing among families with BRCA1/2 or MMR gene mutations. Psychooncology 28(8):1679–1686PubMedCrossRef Alegre N, Perre PV, Bignon YJ, Michel A, Galibert V, Mophawe O, Corsini C, Coupier I, Chiesa J, Robert L et al (2019) Psychosocial and clinical factors of probands impacting intrafamilial disclosure and uptake of genetic testing among families with BRCA1/2 or MMR gene mutations. Psychooncology 28(8):1679–1686PubMedCrossRef
27.
go back to reference Battistuzzi L, Franiuk M, Kasparian N, Rania N, Migliorini L, Varesco L (2019) A qualitative study on decision-making about BRCA1/2 testing in Italian women. Eur J Cancer Care (Engl) 28(5):e13083PubMedCrossRef Battistuzzi L, Franiuk M, Kasparian N, Rania N, Migliorini L, Varesco L (2019) A qualitative study on decision-making about BRCA1/2 testing in Italian women. Eur J Cancer Care (Engl) 28(5):e13083PubMedCrossRef
28.
go back to reference Cragun D, Weidner A, Tezak A, Clouse K, Pal T (2021) Family communication of genetic test results among women with inherited breast cancer genes. J Genet Couns 30(3):701–709PubMedCrossRef Cragun D, Weidner A, Tezak A, Clouse K, Pal T (2021) Family communication of genetic test results among women with inherited breast cancer genes. J Genet Couns 30(3):701–709PubMedCrossRef
29.
go back to reference Daly MB, Montgomery S, Bingler R, Ruth K (2016) Communicating genetic test results within the family: Is it lost in translation? A survey of relatives in the randomized six-step study. Fam Cancer 15(4):697–706PubMedPubMedCentralCrossRef Daly MB, Montgomery S, Bingler R, Ruth K (2016) Communicating genetic test results within the family: Is it lost in translation? A survey of relatives in the randomized six-step study. Fam Cancer 15(4):697–706PubMedPubMedCentralCrossRef
30.
go back to reference Dean M, Tezak AL, Johnson S, Pierce JK, Weidner A, Clouse K, Pal T, Cragun D (2021) Sharing genetic test results with family members of BRCA, PALB2, CHEK2, and ATM carriers. Patient Educ Couns 104(4):720–725PubMedPubMedCentralCrossRef Dean M, Tezak AL, Johnson S, Pierce JK, Weidner A, Clouse K, Pal T, Cragun D (2021) Sharing genetic test results with family members of BRCA, PALB2, CHEK2, and ATM carriers. Patient Educ Couns 104(4):720–725PubMedPubMedCentralCrossRef
31.
go back to reference Dwyer AA, Hesse-Biber S, Shea H, Zeng Z, Yi S (2022) Coping response and family communication of cancer risk in men harboring a BRCA mutation: a mixed methods study. Psychooncology 31(3):486–495PubMedCrossRef Dwyer AA, Hesse-Biber S, Shea H, Zeng Z, Yi S (2022) Coping response and family communication of cancer risk in men harboring a BRCA mutation: a mixed methods study. Psychooncology 31(3):486–495PubMedCrossRef
32.
go back to reference Dwyer AA, Hesse-Biber S, Flynn B, Remick S (2020) Parent of origin effects on family communication of risk in BRCA+ women: a qualitative investigation of human factors in cascade screening. Cancers (Basel) 12(8):2316PubMedCrossRef Dwyer AA, Hesse-Biber S, Flynn B, Remick S (2020) Parent of origin effects on family communication of risk in BRCA+ women: a qualitative investigation of human factors in cascade screening. Cancers (Basel) 12(8):2316PubMedCrossRef
33.
go back to reference Elrick A, Ashida S, Ivanovich J, Lyons S, Biesecker BB, Goodman MS, Kaphingst KA (2017) Psychosocial and clinical factors associated with family communication of cancer genetic test results among women diagnosed with breast cancer at a young age. J Genet Couns 26(1):173–181PubMedCrossRef Elrick A, Ashida S, Ivanovich J, Lyons S, Biesecker BB, Goodman MS, Kaphingst KA (2017) Psychosocial and clinical factors associated with family communication of cancer genetic test results among women diagnosed with breast cancer at a young age. J Genet Couns 26(1):173–181PubMedCrossRef
34.
go back to reference Fehniger J, Lin F, Beattie MS, Joseph G, Kaplan C (2013) Family communication of BRCA1/2 results and family uptake of BRCA1/2 testing in a diverse population of BRCA1/2 carriers. J Genet Couns 22(5):603–612PubMedCrossRef Fehniger J, Lin F, Beattie MS, Joseph G, Kaplan C (2013) Family communication of BRCA1/2 results and family uptake of BRCA1/2 testing in a diverse population of BRCA1/2 carriers. J Genet Couns 22(5):603–612PubMedCrossRef
35.
go back to reference Hesse-Biber S, Dwyer AA, Yi S (2020) Parent of origin differences in psychosocial burden and approach to BRCA risk management. Breast J 26(4):734–738PubMedCrossRef Hesse-Biber S, Dwyer AA, Yi S (2020) Parent of origin differences in psychosocial burden and approach to BRCA risk management. Breast J 26(4):734–738PubMedCrossRef
36.
go back to reference Hoskins LM, Werner-Lin A (2013) A multi-case report of the pathways to and through genetic testing and cancer risk management for BRCA mutation-positive women aged 18–25. J Genet Couns 22(1):27–38PubMedCrossRef Hoskins LM, Werner-Lin A (2013) A multi-case report of the pathways to and through genetic testing and cancer risk management for BRCA mutation-positive women aged 18–25. J Genet Couns 22(1):27–38PubMedCrossRef
37.
go back to reference Katapodi MC, Ming C, Northouse LL, Duffy SA, Duquette D, Mendelsohn-Victor KE, Milliron KJ, Merajver SD, Dinov ID, Janz NK (2020) Genetic testing and surveillance of young breast cancer survivors and blood relatives: a cluster randomized trial. Cancers (Basel) 12(9):2526PubMedCrossRef Katapodi MC, Ming C, Northouse LL, Duffy SA, Duquette D, Mendelsohn-Victor KE, Milliron KJ, Merajver SD, Dinov ID, Janz NK (2020) Genetic testing and surveillance of young breast cancer survivors and blood relatives: a cluster randomized trial. Cancers (Basel) 12(9):2526PubMedCrossRef
38.
go back to reference Katapodi MC, Northouse LL, Milliron KJ, Liu G, Merajver SD (2013) Individual and family characteristics associated with BRCA1/2 genetic testing in high-risk families. Psychooncology 22(6):1336–1343PubMedCrossRef Katapodi MC, Northouse LL, Milliron KJ, Liu G, Merajver SD (2013) Individual and family characteristics associated with BRCA1/2 genetic testing in high-risk families. Psychooncology 22(6):1336–1343PubMedCrossRef
39.
go back to reference Lafrenière D, Bouchard K, Godard B, Simard J, Dorval M (2013) Family communication following BRCA1/2 genetic testing: a close look at the process. J Genet Couns 22(3):323–335PubMedCrossRef Lafrenière D, Bouchard K, Godard B, Simard J, Dorval M (2013) Family communication following BRCA1/2 genetic testing: a close look at the process. J Genet Couns 22(3):323–335PubMedCrossRef
40.
go back to reference Lee DS, Meiser B, Mariapun S, Hassan T, Yip CH, Mohd Taib NA, Teo SH, Thong MK, Yoon SY (2021) Communication about positive BRCA1 and BRCA2 genetic test results and uptake of testing in relatives in a diverse asian setting. J Genet Couns 30(3):720–729PubMedCrossRef Lee DS, Meiser B, Mariapun S, Hassan T, Yip CH, Mohd Taib NA, Teo SH, Thong MK, Yoon SY (2021) Communication about positive BRCA1 and BRCA2 genetic test results and uptake of testing in relatives in a diverse asian setting. J Genet Couns 30(3):720–729PubMedCrossRef
41.
go back to reference Lieberman S, Lahad A, Tomer A, Koka S, BenUziyahu M, Raz A, Levy-Lahad E (2018) Familial communication and cascade testing among relatives of BRCA population screening participants. Genet Med 20(11):1446–1454PubMedCrossRef Lieberman S, Lahad A, Tomer A, Koka S, BenUziyahu M, Raz A, Levy-Lahad E (2018) Familial communication and cascade testing among relatives of BRCA population screening participants. Genet Med 20(11):1446–1454PubMedCrossRef
42.
go back to reference Montgomery SV, Barsevick AM, Egleston BL, Bingler R, Ruth K, Miller SM, Malick J, Cescon TP, Daly MB (2013) Preparing individuals to communicate genetic test results to their relatives: report of a randomized control trial. Fam Cancer 12(3):537–546PubMedPubMedCentralCrossRef Montgomery SV, Barsevick AM, Egleston BL, Bingler R, Ruth K, Miller SM, Malick J, Cescon TP, Daly MB (2013) Preparing individuals to communicate genetic test results to their relatives: report of a randomized control trial. Fam Cancer 12(3):537–546PubMedPubMedCentralCrossRef
43.
go back to reference Seven M, Shah LL, Yazici H, Daack-Hirsch S (2022) From probands to relatives: communication of genetic risk for hereditary breast-ovarian cancer and its influence on subsequent testing. Cancer Nurs 45(1):E91-e98PubMedCrossRef Seven M, Shah LL, Yazici H, Daack-Hirsch S (2022) From probands to relatives: communication of genetic risk for hereditary breast-ovarian cancer and its influence on subsequent testing. Cancer Nurs 45(1):E91-e98PubMedCrossRef
44.
go back to reference Young AL, Butow PN, Rhodes P, Tucker KM, Williams R, Healey E, Wakefield CE (2019) Talking across generations: family communication about BRCA1 and BRCA2 genetic cancer risk. J Genet Couns 28(3):516–532PubMedCrossRef Young AL, Butow PN, Rhodes P, Tucker KM, Williams R, Healey E, Wakefield CE (2019) Talking across generations: family communication about BRCA1 and BRCA2 genetic cancer risk. J Genet Couns 28(3):516–532PubMedCrossRef
45.
go back to reference Zhang Y, Yi S, Trace CB, Williams-Brown MY (2022) Understanding the information needs of patients with ovarian cancer regarding genetic testing to inform intervention design: interview study. JMIR Cancer 8(1):e31263PubMedPubMedCentralCrossRef Zhang Y, Yi S, Trace CB, Williams-Brown MY (2022) Understanding the information needs of patients with ovarian cancer regarding genetic testing to inform intervention design: interview study. JMIR Cancer 8(1):e31263PubMedPubMedCentralCrossRef
46.
go back to reference Witt MM, Jankowska KA (2018) Breaking bad news in genetic counseling—problems and communication tools. J Appl Genet 59(4):449–452PubMedCrossRef Witt MM, Jankowska KA (2018) Breaking bad news in genetic counseling—problems and communication tools. J Appl Genet 59(4):449–452PubMedCrossRef
47.
go back to reference Shah LL, Daack-Hirsch S, Ersig AL, Paik A, Ahmad F, Williams J (2019) Family relationships associated with communication and testing for inherited cardiac conditions. West J Nurs Res 41(11):1576–1601PubMedCrossRef Shah LL, Daack-Hirsch S, Ersig AL, Paik A, Ahmad F, Williams J (2019) Family relationships associated with communication and testing for inherited cardiac conditions. West J Nurs Res 41(11):1576–1601PubMedCrossRef
48.
go back to reference Shah LL, Daack-Hirsch S (2018) Family communication about genetic risk of hereditary cardiomyopathies and arrhythmias: an integrative review. J Genet Couns 27(5):1022–1039PubMedPubMedCentralCrossRef Shah LL, Daack-Hirsch S (2018) Family communication about genetic risk of hereditary cardiomyopathies and arrhythmias: an integrative review. J Genet Couns 27(5):1022–1039PubMedPubMedCentralCrossRef
49.
go back to reference Hurtado-de-Mendoza A, Jackson MC, Anderson L, Sheppard VB (2017) The role of knowledge on genetic counseling and testing in black cancer survivors at increased risk of carrying a BRCA1/2 mutation. J Genet Couns 26(1):113–121PubMedCrossRef Hurtado-de-Mendoza A, Jackson MC, Anderson L, Sheppard VB (2017) The role of knowledge on genetic counseling and testing in black cancer survivors at increased risk of carrying a BRCA1/2 mutation. J Genet Couns 26(1):113–121PubMedCrossRef
50.
51.
go back to reference Erblich J, Brown K, Kim Y, Valdimarsdottir HB, Livingston BE, Bovbjerg DH (2005) Development and validation of a breast cancer genetic counseling knowledge questionnaire. Patient Educ Couns 56(2):182–191PubMedCrossRef Erblich J, Brown K, Kim Y, Valdimarsdottir HB, Livingston BE, Bovbjerg DH (2005) Development and validation of a breast cancer genetic counseling knowledge questionnaire. Patient Educ Couns 56(2):182–191PubMedCrossRef
52.
go back to reference Carere DA, Kraft P, Kaphingst KA, Roberts JS, Green RC (2016) Consumers report lower confidence in their genetics knowledge following direct-to-consumer personal genomic testing. Genet Med 18(1):65–72PubMedCrossRef Carere DA, Kraft P, Kaphingst KA, Roberts JS, Green RC (2016) Consumers report lower confidence in their genetics knowledge following direct-to-consumer personal genomic testing. Genet Med 18(1):65–72PubMedCrossRef
53.
go back to reference Forrest LE, Delatycki MB, Skene L, Aitken M (2007) Communicating genetic information in families–a review of guidelines and position papers. Eur J Hum Genet 15(6):612–618PubMedCrossRef Forrest LE, Delatycki MB, Skene L, Aitken M (2007) Communicating genetic information in families–a review of guidelines and position papers. Eur J Hum Genet 15(6):612–618PubMedCrossRef
54.
go back to reference Kinnamon DD, Jordan E, Haas GJ, Hofmeyer M, Kransdorf E, Ewald GA, Morris AA, Owens A, Lowes B, Stoller D et al (2023) Effectiveness of the family heart talk communication tool in improving family member screening for dilated cardiomyopathy: results of a randomized trial. Circulation 147(17):1281–1290PubMedPubMedCentralCrossRef Kinnamon DD, Jordan E, Haas GJ, Hofmeyer M, Kransdorf E, Ewald GA, Morris AA, Owens A, Lowes B, Stoller D et al (2023) Effectiveness of the family heart talk communication tool in improving family member screening for dilated cardiomyopathy: results of a randomized trial. Circulation 147(17):1281–1290PubMedPubMedCentralCrossRef
55.
go back to reference Petersen J, Koptiuch C, Wu YP, Mooney R, Elrick A, Szczotka K, Keener M, Pappas L, Kanth P, Soisson A et al (2018) Patterns of family communication and preferred resources for sharing information among families with a Lynch syndrome diagnosis. Patient Educ Couns 101(11):2011–2017PubMedPubMedCentralCrossRef Petersen J, Koptiuch C, Wu YP, Mooney R, Elrick A, Szczotka K, Keener M, Pappas L, Kanth P, Soisson A et al (2018) Patterns of family communication and preferred resources for sharing information among families with a Lynch syndrome diagnosis. Patient Educ Couns 101(11):2011–2017PubMedPubMedCentralCrossRef
56.
go back to reference Peters JA, Kenen R, Hoskins LM, Koehly LM, Graubard B, Loud JT, Greene MH (2011) Unpacking the blockers: understanding perceptions and social constraints of health communication in hereditary breast ovarian cancer (HBOC) susceptibility families. J Genet Couns 20(5):450–464PubMedPubMedCentralCrossRef Peters JA, Kenen R, Hoskins LM, Koehly LM, Graubard B, Loud JT, Greene MH (2011) Unpacking the blockers: understanding perceptions and social constraints of health communication in hereditary breast ovarian cancer (HBOC) susceptibility families. J Genet Couns 20(5):450–464PubMedPubMedCentralCrossRef
57.
go back to reference Manchanda R, Loggenberg K, Sanderson S, Burnell M, Wardle J, Gessler S, Side L, Balogun N, Desai R, Kumar A et al (2015) Population testing for cancer predisposing BRCA1/BRCA2 mutations in the ashkenazi-jewish community: a randomized controlled trial. J Natl Cancer Inst 107(1):379PubMedCrossRef Manchanda R, Loggenberg K, Sanderson S, Burnell M, Wardle J, Gessler S, Side L, Balogun N, Desai R, Kumar A et al (2015) Population testing for cancer predisposing BRCA1/BRCA2 mutations in the ashkenazi-jewish community: a randomized controlled trial. J Natl Cancer Inst 107(1):379PubMedCrossRef
58.
go back to reference Andrews L, Meiser B, Apicella C, Tucker K (2004) Psychological impact of genetic testing for breast cancer susceptibility in women of ashkenazi jewish background: a prospective study. Genet Test 8(3):240–247PubMedCrossRef Andrews L, Meiser B, Apicella C, Tucker K (2004) Psychological impact of genetic testing for breast cancer susceptibility in women of ashkenazi jewish background: a prospective study. Genet Test 8(3):240–247PubMedCrossRef
59.
go back to reference Smith AW, Dougall AL, Posluszny DM, Somers TJ, Rubinstein WS, Baum A (2008) Psychological distress and quality of life associated with genetic testing for breast cancer risk. Psychooncology 17(8):767–773PubMedCrossRef Smith AW, Dougall AL, Posluszny DM, Somers TJ, Rubinstein WS, Baum A (2008) Psychological distress and quality of life associated with genetic testing for breast cancer risk. Psychooncology 17(8):767–773PubMedCrossRef
60.
go back to reference Ertmański S, Metcalfe K, Trempała J, Głowacka MD, Lubiński J, Narod SA, Gronwald J (2009) Identification of patients at high risk of psychological distress after BRCA1 genetic testing. Genet Test Mol Biomarkers 13(3):325–330PubMedCrossRef Ertmański S, Metcalfe K, Trempała J, Głowacka MD, Lubiński J, Narod SA, Gronwald J (2009) Identification of patients at high risk of psychological distress after BRCA1 genetic testing. Genet Test Mol Biomarkers 13(3):325–330PubMedCrossRef
61.
go back to reference Oliveri S, Ferrari F, Manfrinati A, Pravettoni G (2018) A systematic review of the psychological implications of genetic testing: a comparative analysis among cardiovascular neurodegenerative and cancer diseases. Front Genet 9:624PubMedPubMedCentralCrossRef Oliveri S, Ferrari F, Manfrinati A, Pravettoni G (2018) A systematic review of the psychological implications of genetic testing: a comparative analysis among cardiovascular neurodegenerative and cancer diseases. Front Genet 9:624PubMedPubMedCentralCrossRef
62.
go back to reference Wiens ME, Wilson BJ, Honeywell C, Etchegary H (2013) A family genetic risk communication framework: guiding tool development in genetics health services. J Community Genet 4(2):233–242PubMedPubMedCentralCrossRef Wiens ME, Wilson BJ, Honeywell C, Etchegary H (2013) A family genetic risk communication framework: guiding tool development in genetics health services. J Community Genet 4(2):233–242PubMedPubMedCentralCrossRef
Metadata
Title
Psychosocial barriers and facilitators for cascade genetic testing in hereditary breast and ovarian cancer: a scoping review
Authors
Agani Afaya
Sung-Won Kim
Hyung Seok Park
Myong Cheol Lim
Mi Sook Jung
Eun Ji Nam
Ji Soo Park
Joon Jeong
Jai Min Ryu
JiSun Kim
Jihye Kim
Minkyoung Kim
Juhye Jin
Jeehee Han
Soo Yeon Kim
Sun-Young Park
Maria C. Katapodi
Sue Kim
the K-CASCADE consortium
Publication date
25-04-2024
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2024
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-024-00379-y

Other articles of this Issue 2/2024

Familial Cancer 2/2024 Go to the issue
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare